

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number  
WO 01/34638 A1

(51) International Patent Classification<sup>7</sup>: C07K 1/113 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US00/30798

(22) International Filing Date: 10 November 2000 (10.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/165,188 12 November 1999 (12.11.1999) US  
09/709,704 9 November 2000 (09.11.2000) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, M/S 27-4-A, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: TREUHEIT, Michael, J.; 824 Pamela Wood Street, Newbury Park, CA 91320 (US). O'CONNER, Sheila, R.; 3208 Spring Meadow Avenue, Thousand Oaks, CA 91360 (US). KOSKY, Andrew, A.; 11867 Tuscana Court, Moorpark, CA 93021 (US).

(74) Agents: ODRE, Steven, M. et al.; Amgen Inc., One Amgen Center Drive, M/S 27-4-A, Thousand Oaks, CA 91320-1799 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/34638 A1

(54) Title: PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES

(57) Abstract: The present invention concerns a process by which a misfold in an Fc fusion molecule can be prevented or corrected. In one embodiment, the process comprises (a) preparing a pharmacologically active compound comprising an Fc domain; (b) treating the fusion molecule with a copper (II) halide; and (c) isolating the treated fusion molecule. The preferred copper (II) halide is CuCl<sub>2</sub>. The preferred concentration thereof is at least about 10 mM for fusion molecules prepared in E. coli; at least about 30 mM for fusion molecules prepared in CHO cells. Preferred pharmacologically active domains include OPG proteins, leptin proteins, soluble portions of TNF receptors (e.g., wherein the fusion molecule is etanercept), IL-1ra proteins, and TPO-mimetic peptides. The Fc domain preferably has a human sequence, with an Fc sequence derived from IgG1 most preferred.

## PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES

### Background of the Invention

5 Recombinant proteins are an emerging class of therapeutic agents. Such recombinant therapeutics have engendered advances in protein formulation and chemical modification. Such modifications can protect therapeutic proteins, primarily by blocking their exposure to proteolytic enzymes. Protein modifications may also increase the therapeutic 10 protein's stability, circulation time, and biological activity. A review article describing protein modification and fusion proteins is Francis (1992), Focus on Growth Factors 3:4-10 (Mediscript, London), which is hereby incorporated by reference.

One useful modification is combination with the "Fc" domain of an 15 antibody. Antibodies comprise two functionally independent parts, a variable domain known as "Fab", which binds antigen, and another domain known as "Fc", which links to such effector functions as complement activation and attack by phagocytic cells. An Fc has a long serum half-life, whereas an Fab is short-lived. Capon *et al.* (1989), Nature 20 337: 525-31. When constructed together with a therapeutic protein, an Fc domain can provide longer half-life or incorporate such functions as Fc receptor binding, protein A binding, complement fixation and perhaps even placental transfer. *Id.* Table 1 summarizes use of Fc fusions known in the art.

25 **Table 1—Fc fusion with therapeutic proteins**

Form of Fc	Fusion partner	Therapeutic implications	Reference
IgG1	N-terminus of CD30-L	Hodgkin's disease; anaplastic lymphoma; T-cell leukemia	U.S. Patent No. 5,480,981
Murine Fc $\gamma$ 2a	IL-10	anti-inflammatory; transplant rejection	Zheng <i>et al.</i> (1995), <u>J. Immunol.</u> 154: 5590-600

IgG1	TNF receptor	septic shock	Fisher <i>et al.</i> (1996), <i>N. Engl. J. Med.</i> 334: 1697-1702; Van Zee, K. <i>et al.</i> (1996), <i>J. Immunol.</i> 156: 2221-30
IgG, IgA, IgM, or IgE (excluding the first domain)	TNF receptor	inflammation, autoimmune disorders	U.S. Pat. No. 5,808,029, issued September 15, 1998
IgG1	CD4 receptor	AIDS	Capon <i>et al.</i> (1989), <i>Nature</i> 337: 525-31
IgG1, IgG3	N-terminus of IL-2	anti-cancer, antiviral	Harvill <i>et al.</i> (1995), <i>Immunotech.</i> 1: 95-105
IgG1	C-terminus of OPG	osteoarthritis; bone density	WO 97/23614, published July 3, 1997
IgG1	N-terminus of leptin	anti-obesity	PCT/US 97/23183, filed December 11, 1997
Human Ig Cy1	CTLA-4	autoimmune disorders	Linsley (1991), <i>J. Exp. Med.</i> 174:561-9

Despite their advantages, use of Fc fusion molecules may be limited by misfolding upon expression in a desired cell line. Such misfolded Fc fusion molecules may generate an immune response *in vivo* or may cause 5 aggregation or stability problems in production.

#### Summary of the Invention

The present invention concerns a process by which a misfold in an Fc fusion molecule can be prevented or corrected. In one embodiment, the process comprises:

10 (a) preparing a fusion molecule comprising (i) a pharmacologically active domain and (ii) an Fc domain;

(b) treating the fusion molecule with a copper (II) halide; and

(c) isolating the treated fusion molecule.

The preferred copper (II) halide is CuCl<sub>2</sub>. The preferred 15 concentration thereof is at least about 10 mM for fusion molecules prepared in *E. coli*; at least about 30 mM for fusion molecules prepared in CHO cells.

An alternative embodiment of the process comprises the following steps:

- (a) preparing a fusion molecule comprising (i) a pharmacologically active domain and (ii) an Fc domain;
- 5 (b) treating the fusion molecule with guanidine HCl at a concentration of at least about 4 M;
- (c) increasing the pH to about 8.5; and
- (d) isolating the treated fusion molecule.

Each of these processes can be employed with any number of 10 pharmacologically active domains. Preferred pharmacologically active domains include OPG proteins, leptin proteins, TNF- $\alpha$  inhibitors (e.g., wherein the fusion molecule is etanercept), IL-1 inhibitors (e.g., IL-1ra proteins, which are preferred), and TPO-mimetic peptides. Also within the claimed process are molecules in which the pharmacologically active 15 compound is an antibody. The Fc domain preferably has a human sequence, with an Fc sequence derived from IgG1 most preferred. An exemplary Fc sequence is shown in Figure 5 hereinafter.

Although mostly contemplated as therapeutic agents, compounds 20 of this invention may also be useful in screening for such agents. For example, one could use an Fc-peptide (e.g., Fc-SH2 domain peptide) in an assay employing anti-Fc coated plates. The vehicle, especially Fc, may make insoluble peptides soluble and thus useful in a number of assays.

The compounds prepared by the process of this invention may be 25 used for therapeutic or prophylactic purposes by formulating them with appropriate pharmaceutical carrier materials and administering an effective amount to a patient, such as a human (or other mammal) in need thereof.

Numerous additional aspects and advantages of the present invention will become apparent upon consideration of the figures and detailed description of the invention.

#### Brief Description of the Figures

5       Figure 1. Reversed-phase high performance liquid chromatography (RP-HPLC) chromatogram showing Fc-OPG prepared in E. coli with and without treatment with 10 mM CuCl<sub>2</sub>. At a concentration of 10 mM, CuCl<sub>2</sub> causes complete irreversible elimination of the RP post-peak.

10      Figure 2. RP-HPLC chromatogram showing Fc-OPG prepared in E. coli treated with CDAP. The RP post-peak molecular weight increased by 52 Da.

15      Figure 3. RP-HPLC chromatogram showing Fc-OPG prepared in E. coli treated with CDAP and subsequently subjected to base cleavage. The base cleavage reveals that cysteines 148 and 206 were labeled by CDAP.

20      Figure 4. RP-HPLC chromatogram showing Fc-OPG prepared in CHO cells, with and without treatment with 30 mM CuCl<sub>2</sub>. At a concentration of 30 mM, CuCl<sub>2</sub> causes complete irreversible elimination of the RP post-peak.

25      Figure 5. Exemplary nucleic acid and amino acid sequences (SEQ ID NOS: 1 and 2, respectively) of a human IgG1 Fc that may be used in this invention.

          Figure 6. Reaction scheme showing cyanylation of cysteine residues in acidic conditions with CDAP.

          Figure 7. Reaction scheme showing cleavage of the cyanlated cysteine by ammonia. Under alkaline and denaturing conditions (1.5N NH<sub>4</sub>OH and 4M GdHCl), the protein backbone undergoes cleavage at the carbonyl-amide peptide bond on the cyanlated cysteine. The result is an

amidated N-terminal peptide and an iminothiazolidine (ITZ) peptide which are separated and identified by LC-MS.

Figure 8. RP- HPLC chromatograms with mass spectrometry determined molecular weights of Fc-OPG (A), Fc-OPG reacted with CuCl<sub>2</sub> 5 (B), and Fc-OPG reacted with CDAP followed by CuCl<sub>2</sub> (C).

Figure 9. RP-HPLC chromatograms of purified main and isoform peaks following CDAP reaction and cleavage.

Figure 10. Schematic diagram of the Fc-OPG construct, CDAP- cleavage pattern and the missing Fc-domain disulfide linkage that results 10 in the RP-HPLC isoform.

Figure 11. Reversed-phase HPLC of untreated (upper trace) and copper-treated (lower trace) Fc-OPG.

Figure 12. Size-exclusion HPLC of Fc-OPG after 2 years incubation at 29 °C; copper-treated Fc-OPG (lower trace) and untreated Fc-OPG 15 (upper trace).

### Detailed Description of the Invention

#### In General

In production of therapeutic proteins by recombinant techniques, the therapeutic protein quite often must be refolded to an active 20 conformation. At present, the refold process includes an oxidation step to form the disulfide structure of the produced recombinant protein. The reagents commonly used to catalyze formation of the disulfide structure are the free amino acids cysteine/cystamine at a pH of 8-9. In addition, copper sulfate at a copper concentration in the micromolar range can also 25 be used. For refolding of Fc fusion molecules, however, copper sulfate cannot be used due to the high levels of arginine (0.5 M) which is a chelator of Cu<sup>+</sup>. Remaining misfolds are normally removed during the subsequent purification process. After process purification of Fc-OPG, for example, a post-peak was isolated by reversed-phase (RP) high

performance liquid chromatography (HPLC). Data (primarily from peptide maps and Ellmann's reagent) suggested the RP post-peak did not contain free thiols.

In the course of formulation development, the effects of mono- and 5 divalent cations can be related to increases in various chemical degradations. During the screening of Fc-OPG, it was observed that 1 mM CuCl<sub>2</sub> had a dramatic effect at reducing the amount of the RP post-peak. Subsequent experiments have shown that 10 mM CuCl<sub>2</sub> is required for the 10 complete irreversible elimination of the RP post-peak (see Figure 1). The RP post-peak was shown to result from an unpaired disulfide through the use of the reagent 1-cyano-4-dimethylamino-pyridinium tetrafluoroborate (CDAP). For each free sulphydryl, CDAP adds a CN group or increases 15 the molecular weight by 26 Da. Treating Fc-OPG with CDAP and subsequent HPLC/MS analysis indicated that the molecular weight of the Fc-OPG RP post-peak increased by 52 Da or the equivalent of two 20 sulphydryl groups labeled (see Figure 2). The molecular weight of the RP main-peak did not change after treating with CDAP. Subsequent base cleavage of the cyanylated RP post-peak indicated that only cysteines 148 and 206 (Figure 3) are labeled by CDAP. The disulfide, cys148-cys206, 25 which is not formed in the RP post-peak is found in the CH3 region, which is the second disulfide loop of Fc and is the same disulfide that was difficult to form in Fc-Leptin. Further, pretreatment with CuCl<sub>2</sub> followed by labeling with CDAP produces no detectable change in molecular weight, supporting the conclusion that Cu<sup>++</sup> fixes the disulfide problem in 30 Fc-OPG. Similar results utilizing CuCl<sub>2</sub> have been observed for the CHO-OPG-Fc (Figure 4) and allows us to conclude that all of our recombinant Fc molecules have the same difficulty in forming the disulfide in the CH3 region of Fc. Surprisingly, CHO cells have the same difficulty in Fc disulfide formation to approximately the same degree.

Alternatively the process could be effected as a post-refold treatment. Several methods can be used to eliminate the RP post-peak. In addition to the CuCl<sub>2</sub> treatment, a similar removal of post-peak is observed after denaturing in a minimum of 4 M guanidine HCl and 5 increasing the pH from 5.0 to 8.5. Both treatments strongly support that free thiols are involved which can be converted to a disulfide.

#### Definition of Terms

The terms used throughout this specification are defined as follows, unless otherwise limited in specific instances.

10 The term "comprising" means that a compound may include additional amino acids on either or both of the N- or C- termini of the given sequence. Of course, these additional amino acids should not significantly interfere with the activity of the compound.

15 The term "native Fc" refers to molecule or sequence comprising the sequence of a non-antigen-binding fragment resulting from digestion of whole antibody, whether in monomeric or multimeric form. The original immunoglobulin source of the native Fc is preferably of human origin and may be any of the immunoglobulins, although IgG1 and IgG2 are preferred. Native Fc's are made up of monomeric polypeptides that may 20 be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, IgGA2). One example of a native Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG (see Ellison *et al.* 25 (1982), Nucleic Acids Res. 10: 4071-9). The term "native Fc" as used herein is generic to the monomeric, dimeric, and multimeric forms.

The term "Fc variant" refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage

receptor, FcRn. International applications WO 97/34631 (published 25 September 1997) and WO 96/32478 describe exemplary Fc variants, as well as interaction with the salvage receptor, and are hereby incorporated by reference. Thus, the term "Fc variant" comprises a molecule or

5 sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises sites that may be removed because they provide structural features or biological activity that are not required for the fusion molecules of the present invention. Thus, the term "Fc variant" comprises a molecule or sequence that lacks one or more native Fc sites or residues

10 that affect or are involved in (1) disulfide bond formation, (2) incompatibility with a selected host cell (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC). Fc variants are

15 described in further detail hereinafter.

The term "Fc domain" encompasses native Fc and Fc variant molecules and sequences as defined above. As with Fc variants and native Fc's, the term "Fc domain" includes molecules in monomeric or multimeric form, whether digested from whole antibody or produced by

20 other means.

The term "multimer" as applied to Fc domains or molecules comprising Fc domains refers to molecules having two or more polypeptide chains associated covalently, noncovalently, or by both covalent and non-covalent interactions. IgG molecules typically form

25 dimers; IgM, pentamers; IgD, dimers; and IgA, monomers, dimers, trimers, or tetramers. Multimers may be formed by exploiting the sequence and resulting activity of the native Ig source of the Fc or by derivatizing (as defined below) such a native Fc.

The term "dimer" as applied to Fc domains or molecules comprising Fc domains refers to molecules having two polypeptide chains associated covalently or non-covalently.

The terms "derivatizing" and "derivative" or "derivatized" 5 comprise processes and resulting compounds respectively in which (1) the compound has a cyclic portion; for example, cross-linking between cysteinyl residues within the compound; (2) the compound is cross-linked or has a cross-linking site; for example, the compound has a cysteinyl residue and thus forms cross-linked dimers in culture or in vivo; (3) one or 10 more peptidyl linkage is replaced by a non-peptidyl linkage; (4) the N-terminus is replaced by -NRR<sup>1</sup>, NRC(O)R<sup>1</sup>, -NRC(O)OR<sup>1</sup>, -NRS(O)<sub>2</sub>R<sup>1</sup>, -NHC(O)NHR, a succinimide group, or substituted or unsubstituted benzylloxycarbonyl-NH-, wherein R and R<sup>1</sup> and the ring substituents are as defined hereinafter; (5) the C-terminus is replaced by -C(O)R<sup>2</sup> or -NR<sup>3</sup>R<sup>4</sup> 15 wherein R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined hereinafter; and (6) compounds in which individual amino acid moieties are modified through treatment with agents capable of reacting with selected side chains or terminal residues. Derivatives are further described hereinafter.

The term "peptide" refers to molecules of 3 to 40 amino acids, with 20 molecules of 3 to 20 amino acids preferred and those of 6 to 15 amino acids most preferred. Exemplary peptides may be randomly generated by any of the methods cited above, carried in a phage display library, or derived by digestion of proteins.

The term "native protein" refers to a molecule having an amino acid 25 sequence that may be isolated from an organism without modification by recombinant DNA techniques or other methods.

The term "protein fragment" refers to a molecule or sequence that comprises only a portion of the sequence of a native protein but still retains the pharmacological activity of interest. The term "protein

fragment" thus comprises, for example, the soluble domain of a cellular receptor (e.g., a receptor for tumor necrosis factor).

The term "protein variant" refers to a molecule or sequence that is modified from a native protein but still retains the pharmacological activity of interest. Thus, the term "protein variant" comprises a molecule or sequence in which non-native residues substitute for native residues, non-native residues are added, or native residues are deleted. Any native residue may be removed because it provides structural features or biological activity that are not required for the pharmacological activity of interest of the fusion molecules of the present invention. Thus, the term "protein variant" comprises a molecule or sequence that lacks one or more native protein sites or residues that affect or are involved in (1) intracellular signaling, (2) incompatibility with a selected host cell (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with other proteins (e.g., dimerization domains), (6) binding to a receptor or other protein that does not affect the pharmacological activity of interest, or (7) antibody-dependent cellular cytotoxicity (ADCC). Fc variants are described in further detail hereinafter.

The terms "derivatizing" and "derivative" or "derivatized" as used with respect to proteins refers to proteins in which (1) the protein is modified to include a cyclic portion; for example, cross-linking between cysteinyl residues within the compound; (2) the compound is cross-linked or has a cross-linking site; for example, the compound has a cysteinyl residue and thus forms cross-linked dimers in culture or in vivo; (3) one or more peptidyl linkage is replaced by a non-peptidyl linkage; (4) the N-terminus is replaced by -NRR<sup>1</sup>, NRC(O)R<sup>1</sup>, -NRC(O)OR<sup>1</sup>, -NRS(O)<sub>2</sub>R<sup>1</sup>, -NHC(O)NHR, a succinimide group, or substituted or unsubstituted benzyloxycarbonyl-NH-, wherein R and R<sup>1</sup> and the ring substituents are

as defined hereinafter; (5) the C-terminus is replaced by -C(O)R<sup>2</sup> or -NR<sup>3</sup>R<sup>4</sup> wherein R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined hereinafter; and (6) compounds in which individual amino acid moieties are modified through treatment with agents capable of reacting with selected side chains or terminal residues. Derivatives are further described hereinafter.

5 The term "polypeptide" refers to native proteins, protein variants, protein derivatives, and protein fragments.

10 The term "pharmacologically active" means that a substance so described is determined to have activity that affects a medical parameter (e.g., blood pressure, blood cell count, cholesterol level) or disease state (e.g., cancer). Thus, pharmacologically active peptides comprise agonistic or mimetic and antagonistic peptides as defined below.

15 The term "OPG protein" refers collectively to the novel member of the tumor necrosis factor receptor family described in International patent application WO 97/23614. Exemplary OPG proteins are polypeptides comprising the rat, mouse or human OPG sequences or a consensus of the rat, mouse and human sequences.

20 The term "TNF- $\alpha$  inhibitor" thus includes solubilized TNF receptors, antibodies to TNF, antibodies to TNF receptor, inhibitors of TNF- $\alpha$  converting enzyme (TACE), and other molecules that affect TNF activity.

TNF- $\alpha$  inhibitors of various kinds are disclosed in the art, including the following references:

25 European patent applications 308 378; 422 339; 393 438; 398 327; 412 486; 418 014, 417 563, 433 900; 464 533; 512 528; 526 905; 568 928; 663 210; 542 795; 818 439; 664 128; 542 795; 741 707; 874 819; 882 714; 880 970; 648 783; 731 791; 895 988; 550 376; 882 714; 853 083; 550 376; 943 616;

U.S. Patent Nos. 5,136,021; 5,929,117; 5,948,638; 5,807,862; 5,695,953; 5,834,435; 5,817,822; 5830742; 5,834,435; 5,851,556; 5,853,977; 5,359,037;

5,512,544; 5,695,953; 5,811,261; 5,633,145; 5,863,926; 5,866,616; 5,641,673; 5,869,677; 5,869,511; 5,872,146; 5,854,003; 5,856,161; 5,877,222; 5,877,200; 5,877,151; 5,886,010; 5,869,660; 5,859,207; 5,891,883; 5,877,180; 5,955,480; 5,955,476; 5,955,435.

5        International(WO)patent applications 90/13575, 91/03553, 92/01002, 92/13095, 92/16221, 93/07863, 93/21946, 93/19777, 95/34326, 96/28546, 98/27298, 98/30541, 96/38150, 96/38150, 97/18207, 97/15561, 97/12902, 96/25861, 96/12735, 96/11209, 98/39326, 98/39316, 98/38859, 98/39315, 98/42659, 98/39329, 98/43959, 98/45268, 98/47863, 96/33172, 10      96/20926, 97/37974, 97/37973, 96/35711, 98/51665, 98/43946, 95/04045, 98/56377, 97/12244, 99/00364, 99/00363, 98/57936, 99/01449, 99/01139, 98/56788, 98/56756, 98/53842, 98/52948, 98/52937, 99/02510, 97/43250, 99/06410, 99/06042, 99/09022, 99/08688, 99/07679, 99/09965, 99/07704, 99/06041, 99/37818, 99/37625, 97/11668;

15      Japanese (JP) patent applications 10147531, 10231285, 10259140, and 10130149, 10316570, 11001481, and 127,800/1991; German (DE) application 19731521; British (GB) applications 2 218 101, 2 326 881, 2 246 569.

20      The disclosures of all of the aforementioned references are hereby incorporated by reference.

25      The term "interleukin-1 inhibitor" refers to a polypeptide capable of specifically preventing activation of cellular receptors to IL-1, which may result from any number of mechanisms. Such mechanisms include downregulating IL-1 production, binding free IL-1, interfering with IL-1 binding to its receptor, interfering with formation of the IL-1 receptor complex (i.e., association of IL-1 receptor with IL-1 receptor accessory protein), or interfering with modulation of IL-1 signaling after binding to its receptor. Classes of interleukin-1 inhibitors include:

interleukin-1 receptor antagonists such as IL-1ra, as described below;

CDRs or entire variable regions of anti-IL-1 receptor monoclonal antibodies (e.g., EP 623674), the disclosure of which is hereby incorporated by reference;

5 IL-1 binding proteins such as soluble IL-1 receptors (e.g., U. S. Pat. No. 5,492,888, U. S. Pat. No. 5,488,032, and U. S. Pat. No. 5,464,937, U. S. Pat. No. 5,319,071, and U. S. Pat. No. 5,180,812, the disclosures of which are hereby incorporated by reference);

10 CDRs or entire variable regions of anti-IL-1 monoclonal antibodies (e.g., WO 9501997, WO 9402627, WO 9006371, U. S. Pat. No. 4,935,343, EP 364778, EP 267611 and EP 220063, the disclosures of which are hereby incorporated by reference);

15 IL-1 receptor accessory proteins and antibodies thereto (e.g., WO 96/23067, the disclosure of which is hereby incorporated by reference);  
inhibitors of interleukin-1 beta converting enzyme (ICE) or caspase I, which can be used to inhibit IL-1 beta production and secretion;  
interleukin-1 beta protease inhibitors;  
and other compounds and proteins which block in vivo synthesis or  
20 extracellular release of IL-1.

Exemplary IL-1 inhibitors are disclosed in the following references:  
US Pat. Nos. 5747444; 5359032; 5608035; 5843905; 5359032; 5866576;  
5869660; 5869315; 5872095; 5955480  
International (WO) patent applications 98/21957, 96/09323,  
25 91/17184, 96/40907, 98/32733, 98/42325, 98/44940, 98/47892, 98/56377,  
99/03837, 99/06426, 99/06042, 91/17249, 98/32733, 98/17661, 97/08174,  
95/34326, 99/36426, and 99/36415.

European (EP) patent applications 534978 and 894795.

French patent application FR 2762514.

The disclosures of all of the aforementioned references are hereby incorporated by reference.

For purposes of the present invention, IL-1ra and variants and derivatives thereof as discussed hereinafter are collectively termed "IL-1ra 5 protein(s)". The molecules described in the above references and the variants and derivatives thereof discussed hereinafter are collectively termed "IL-1 inhibitors."

The term "TPO-mimetic peptide" comprises peptides that can be identified or derived as described in Cwirla *et al.* (1997), *Science* 276: 1696-10 9, U.S. Pat. Nos. 5,869,451 and 5,932,946 and any other reference in Table 2 identified as having TPO-mimetic subject matter, as well as the U.S. patent application, "Thrombopoietic Compounds," filed on October 22, 1999 and hereby incorporated by reference. Those of ordinary skill in the art appreciate that each of these references enables one to select different 15 peptides than actually disclosed therein by following the disclosed procedures with different peptide libraries.


The term "leptin protein" refers to native leptin protein and portions of native leptin protein that retain its anti-diabetes or anti-obesity activity. Exemplary leptin protein sequence is disclosed in PCT/US 20 97/23183, filed December 11, 1997, which is hereby incorporated by reference.

Additionally, physiologically acceptable salts of the compounds of this invention are also encompassed herein. By "physiologically acceptable salts" is meant any salts that are known or later discovered to 25 be pharmaceutically acceptable. Some specific examples are: acetate; trifluoroacetate; hydrohalides, such as hydrochloride and hydrobromide; sulfate; citrate; tartrate; glycolate; and oxalate.

### Structure of compounds

In General. The process of this invention is useful in preparation of compositions of matter in which an Fc domain may be attached to the pharmacologically active molecule through the molecule's N-terminus or 5 C-terminus. Thus, the Fc fusion molecules of this invention may be described by the following formula I:

I



wherein:

10  $F^1$  is an Fc domain;

$X^1$  and  $X^2$  are each independently selected from  $-(L^1)_c-P^1$  and  $-(L^1)_c-P^1-(L^2)_d-P^2$ ;

$P^1$  and  $P^2$  are each independently sequences of pharmacologically active peptides or polypeptides;

15  $L^1$  and  $L^2$  are each independently linkers; and

$a$ ,  $b$ ,  $c$ , and  $d$  are each independently 0 or 1, provided that at least one of  $a$  and  $b$  is 1.

Thus, compound I comprises preferred compounds of the formulae

II




and multimers thereof wherein  $F^1$  is attached at the C-terminus of  $X^1$ ;

III



and multimers thereof wherein  $F^1$  is attached at the N-terminus of  $X^2$ ;

25 IV



and multimers thereof wherein  $F^1$  is attached at the N-terminus of  $-(L^1)_c-P^1$ ;

and

V



and multimers thereof wherein  $F^1$  is attached at the N-terminus of  $-L^1-P^1-L^2-P^2$ .

Peptides. Any number of peptides may be used in conjunction with 5 the present invention. Of particular interest are peptides that mimic the activity of EPO, TPO, growth hormone, G-CSF, GM-CSF, IL-1ra, leptin, CTLA4, TRAIL, TGF- $\alpha$ , and TGF- $\beta$ . Peptide antagonists are also of interest, particularly those antagonistic to the activity of TNF, leptin, any of the interleukins (IL-1, 2, 3, ...), and proteins involved in complement 10 activation (e.g., C3b). These peptides may be discovered by methods described in the references cited in this specification and other references.

Phage display, in particular, is useful in generating peptides for use in the present invention. It has been stated that affinity selection from 15 libraries of random peptides can be used to identify peptide ligands for any site of any gene product. Dedman *et al.* (1993), *J. Biol. Chem.* 268: 23025-30. Phage display is particularly well suited for identifying peptides that bind to such proteins of interest as cell surface receptors or any 20 proteins having linear epitopes. Wilson *et al.* (1998), *Can. J. Microbiol.* 44: 313-29; Kay *et al.* (1998), *Drug Disc. Today* 3: 370-8. Such proteins are extensively reviewed in Herz *et al.* (1997), *J. Receptor & Signal 25 Transduction Res.* 17(5): 671-776, which is hereby incorporated by reference. Such proteins of interest are preferred for use in this invention. Numerous peptides of interest are described in the U.S. patent application entitled, "Modified Peptides as Therapeutic Agents," filed October 22, 1999, which is hereby incorporated by reference.

Polypeptides. Numerous polypeptides suitable for use with the subject invention are known in the art. Suitable proteins include hormones (e.g., growth hormone), cytokines (e.g., IL-1ra), and soluble

receptors (e.g., tumor necrosis factor receptors I and II). Exemplary polypeptides are those listed in Table 1 (see above).

Fc fusion. An Fc domain may be fused to the N or C termini of the pharmacologically active molecule or at both the N and C termini.

5 As noted above, Fc variants are suitable vehicles within the scope of this invention. A native Fc may be extensively modified to form an Fc variant in accordance with this invention, provided binding to the salvage receptor is maintained; see, for example WO 97/34631 and WO 96/32478. In such Fc variants, one may remove one or more sites of a native Fc that 10 provide structural features or functional activity not required by the fusion molecules of this invention. One may remove these sites by, for example, substituting or deleting residues, inserting residues into the site, or truncating portions containing the site. The inserted or substituted residues may also be altered amino acids, such as peptidomimetics or D- 15 amino acids. Fc variants may be desirable for a number of reasons, several of which are described below. Exemplary Fc variants include molecules and sequences in which:

1. Sites involved in disulfide bond formation are removed. Such removal may avoid reaction with other cysteine-containing 20 proteins present in the host cell used to produce the molecules of the invention. For this purpose, the cysteine-containing segment at the N-terminus may be truncated or cysteine residues may be deleted or substituted with other amino acids (e.g., alanyl, seryl). In particular, one may truncate the N- 25 terminal 20-amino acid segment of SEQ ID NO: 2 or delete or substitute the cysteine residues at positions 7 and 10 of SEQ ID NO: 2. Even when cysteine residues are removed, the single chain Fc domains can still form a dimeric Fc domain that is held together non-covalently.

2. A native Fc is modified to make it more compatible with a selected host cell. For example, one may remove the PA sequence near the N-terminus of a typical native Fc, which may be recognized by a digestive enzyme in E. coli such as proline iminopeptidase. One may also add an N-terminal methionine residue, especially when the molecule is expressed recombinantly in a bacterial cell such as E. coli. The Fc domain of SEQ ID NO: 2 (Figure 5) is one such Fc variant.
- 5 3. A portion of the N-terminus of a native Fc is removed to prevent N-terminal heterogeneity when expressed in a selected host cell. For this purpose, one may delete any of the first 20 amino acid residues at the N-terminus, particularly those at positions 1, 2, 3, 10 4 and 5.
- 15 4. One or more glycosylation sites are removed. Residues that are typically glycosylated (e.g., asparagine) may confer cytolytic response. Such residues may be deleted or substituted with unglycosylated residues (e.g., alanine).
- 20 5. Sites involved in interaction with complement, such as the C1q binding site, are removed. For example, one may delete or substitute the EKK sequence of human IgG1. Complement recruitment may not be advantageous for the molecules of this invention and so may be avoided with such an Fc variant.
- 25 6. Sites are removed that affect binding to Fc receptors other than a salvage receptor. A native Fc may have sites for interaction with certain white blood cells that are not required for the fusion molecules of the present invention and so may be removed.
7. The ADCC site is removed. ADCC sites are known in the art; see, for example, Molec. Immunol. 29 (5): 633-9 (1992) with regard to ADCC sites in IgG1. These sites, as well, are not

required for the fusion molecules of the present invention and so may be removed.

5        8. When the native Fc is derived from a non-human antibody, the native Fc may be humanized. Typically, to humanize a native Fc, one will substitute selected residues in the non-human native Fc with residues that are normally found in human native Fc. Techniques for antibody humanization are well known in the art.

10        Linkers. Any "linker" group is optional. When present, its chemical structure is not critical, since it serves primarily as a spacer. The linker is preferably made up of amino acids linked together by peptide bonds. Thus, in preferred embodiments, the linker is made up of from 1 to 20 amino acids linked by peptide bonds, wherein the amino acids are selected from the 20 naturally occurring amino acids. Some of these amino acids  
15        may be glycosylated, as is well understood by those in the art. In a more preferred embodiment, the 1 to 20 amino acids are selected from glycine, alanine, proline, asparagine, glutamine, and lysine. Even more preferably, a linker is made up of a majority of amino acids that are sterically unhindered, such as glycine and alanine. Thus, preferred linkers are  
20        polyglycines, poly(Gly-Ala), and polyalanines. Other specific examples of linkers are:


(Gly)<sub>3</sub>Lys(Gly)<sub>4</sub>;  
(Gly)<sub>3</sub>AsnGlySer(Gly)<sub>2</sub>;  
(Gly)<sub>3</sub>Cys(Gly)<sub>4</sub>; and  
25        GlyProAsnGlyGly.

To explain the above nomenclature, for example, (Gly)<sub>3</sub>Lys(Gly)<sub>4</sub> means Gly-Gly-Gly-Lys-Gly-Gly-Gly. Combinations of Gly and Ala are also preferred. The linkers shown here are exemplary; linkers within the scope of this invention may be much longer and may include other residues.

Non-peptide linkers are also possible. For example, alkyl linkers such as  $-\text{NH}-(\text{CH}_2)_s-\text{C}(\text{O})-$ , wherein  $s = 2-20$  could be used. These alkyl linkers may further be substituted by any non-sterically hindering group such as lower alkyl (e.g.,  $\text{C}_1-\text{C}_6$ ) lower acyl, halogen (e.g., Cl, Br), CN, NH, phenyl, etc. An exemplary non-peptide linker is a PEG linker,

5 phenyl, etc. An exemplary non-peptide linker is a PEG linker,

VI



wherein n is such that the linker has a molecular weight of 100 to 5000 kD, preferably 100 to 500 kD. The peptide linkers may be altered to form derivatives in the same manner as described above.

Derivatives. The inventors also contemplate derivatizing the peptide, polypeptide and/or Fc portion of the compounds. Such derivatives may improve the solubility, absorption, biological half life, and the like of the compounds. The moieties may alternatively eliminate or attenuate any undesirable side-effect of the compounds and the like.


Exemplary derivatives include compounds in which:

20 1. The compound or some portion thereof is cyclic. For example, the pharmacologically active portion (i.e., peptide or polypeptide) may be modified to contain two or more Cys residues (e.g., in the linker), which could cyclize by disulfide bond formation. For citations to references on preparation of cyclized derivatives, see Table 2.

25 2. The compound is cross-linked or is rendered capable of cross-linking between molecules. For example, the pharmacologically active portion may be modified to contain one Cys residue and thereby be able to form an intermolecular disulfide bond with a

like molecule. The compound may also be cross-linked through its C-terminus, as in the molecule shown below.

VII



5        3 . One or more peptidyl [-C(O)NR-] linkages (bonds) is replaced by a non-peptidyl linkage. Exemplary non-peptidyl linkages are -CH<sub>2</sub>-carbamate [-CH<sub>2</sub>-OC(O)NR-], phosphonate, -CH<sub>2</sub>-sulfonamide [-CH<sub>2</sub>-S(O)<sub>2</sub>NR-], urea [-NHC(O)NH-], -CH<sub>2</sub>-secondary amine, and alkylated peptide [-C(O)NR<sup>6</sup>- wherein R<sup>6</sup> is lower alkyl].

10      4. The N-terminus is derivatized. Typically, the N-terminus may be acylated or modified to a substituted amine. Exemplary N-terminal derivative groups include -NRR<sup>1</sup> (other than -NH<sub>2</sub>), -NRC(O)R<sup>1</sup>, -NRC(O)OR<sup>1</sup>, -NRS(O)<sub>2</sub>R<sup>1</sup>, -NHC(O)NHR<sup>1</sup>, succinimide, or benzyloxycarbonyl-NH- (CBZ-NH-), wherein R and R<sup>1</sup> are each independently hydrogen or lower alkyl and wherein the phenyl ring may be substituted with 1 to 3 substituents selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, chloro, and bromo.

15      5. The free C-terminus is derivatized. Typically, the C-terminus is esterified or amidated. Exemplary C-terminal derivative groups include, for example, -C(O)R<sup>2</sup> wherein R<sup>2</sup> is lower alkoxy or -NR<sup>3</sup>R<sup>4</sup> wherein R<sup>3</sup> and R<sup>4</sup> are independently hydrogen or C<sub>1</sub>-C<sub>8</sub> alkyl (preferably C<sub>1</sub>-C<sub>4</sub> alkyl).

20

25

6. A disulfide bond is replaced with another, preferably more stable, cross-linking moiety (e.g., an alkylene). See, e.g., Bhatnagar *et al.* (1996), *J. Med. Chem.* 39: 3814-9; Alberts *et al.* (1993) *Thirteenth Am. Pep. Symp.*, 357-9.

5

7. One or more individual amino acid residues is modified.

Various derivatizing agents are known to react specifically with selected sidechains or terminal residues, as described in detail below.

Lysinyl residues and amino terminal residues may be reacted with

10 succinic or other carboxylic acid anhydrides, which reverse the charge of the lysinyl residues. Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction

15 with glyoxylate.

Arginyl residues may be modified by reaction with any one or combination of several conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginyl residues requires that the reaction be performed in alkaline conditions because

20 of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

Specific modification of tyrosyl residues has been studied extensively, with particular interest in introducing spectral labels into tyrosyl residues by

25 reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.

Carboxyl sidechain groups (aspartyl or glutamyl) may be selectively modified by reaction with carbodiimides ( $R'-N=C=N-R'$ ) such as 1-cyclohexyl-

3-(2-morpholiny1-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues may be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

5       Glutaminyl and asparaginyl residues may be deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

10      Cysteinyl residues can be replaced by amino acid residues or other 15     moieties either to eliminate disulfide bonding or, conversely, to stabilize cross-linking. See, e.g., Bhatnagar *et al.* (1996), *J. Med. Chem.* 39: 3814-9.

15      Derivatization with bifunctional agents is useful for cross-linking the peptides or their functional derivatives to a water-insoluble support matrix or to other macromolecular vehicles. Commonly used cross-linking agents 20     include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, 25     homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive 30     water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Pat. Nos. 3,969,287; 3,691,016; 35     4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein 40     immobilization.

45      Carbohydrate (oligosaccharide) groups may conveniently be attached to sites that are known to be glycosylation sites in proteins. Generally, O-linked oligosaccharides are attached to serine (Ser) or threonine (Thr) residues while N-linked oligosaccharides are attached to

asparagine (Asn) residues when they are part of the sequence Asn-X-Ser/Thr, where X can be any amino acid except proline. X is preferably one of the 19 naturally occurring amino acids other than proline. The structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type are different. One type of sugar that is commonly found on both is N-acetylneurameric acid (referred to as sialic acid). Sialic acid is usually the terminal residue of both N-linked and O-linked oligosaccharides and, by virtue of its negative charge, may confer acidic properties to the glycosylated compound. Such site(s) may be incorporated in the linker of the compounds of this invention and are preferably glycosylated by a cell during recombinant production of the polypeptide compounds (e.g., in mammalian cells such as CHO, BHK, COS). However, such sites may further be glycosylated by synthetic or semi-synthetic procedures known in the art.

Other possible modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, oxidation of the sulfur atom in Cys, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains. Creighton, Proteins: Structure and Molecule Properties (W. H. Freeman & Co., San Francisco), pp. 79-86 (1983).

Compounds prepared in the process of the present invention may be changed at the DNA level, as well. The DNA sequence of any portion of the compound may be changed to codons more compatible with the chosen host cell. For E. coli, which is the preferred host cell, optimized codons are known in the art. Codons may be substituted to eliminate restriction sites or to include silent restriction sites, which may aid in processing of the DNA in the selected host cell. The vehicle, linker and peptide DNA sequences may be modified to include any of the foregoing sequence changes.

### Methods of Making

The compounds prepared in the process of this invention largely may be made in transformed host cells using recombinant DNA techniques. To do so, a recombinant DNA molecule coding for the peptide 5 is prepared. Methods of preparing such DNA molecules are well known in the art. For instance, sequences coding for the peptides could be excised from DNA using suitable restriction enzymes. Alternatively, the DNA molecule could be synthesized using chemical synthesis techniques, such as the phosphoramidate method. Also, a combination of these techniques 10 could be used.

This invention also contemplates that a vector capable of expressing the molecules in an appropriate host. The vector comprises the DNA molecule that codes for the molecule operatively linked to appropriate expression control sequences. Methods of effecting this operative linking, 15 either before or after the DNA molecule is inserted into the vector, are well known. Expression control sequences include promoters, activators, enhancers, operators, ribosomal binding sites, start signals, stop signals, cap signals, polyadenylation signals, and other signals involved with the control of transcription or translation.

20 The resulting vector having the DNA molecule thereon is used to transform an appropriate host. This transformation may be performed using methods well known in the art.

Any of a large number of available and well-known host cells may 25 be used in the practice of this invention. The selection of a particular host is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the

understanding that not all hosts may be equally effective for the expression of a particular DNA sequence. Within these general guidelines, useful microbial hosts include bacteria (such as E. coli sp.), yeast (such as Saccharomyces sp.) and other fungi, insects, plants, mammalian (including 5 human) cells in culture, or other hosts known in the art.

Next, the transformed host is cultured and purified. Host cells may be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art. Finally, the peptides are purified from culture by 10 methods well known in the art.

The compounds may also be made by synthetic methods. For example, solid phase synthesis techniques may be used. Suitable techniques are well known in the art, and include those described in Merrifield (1973), Chem. Polypeptides, pp. 335-61 (Katsoyannis and 15 Panayotis eds.); Merrifield (1963), J. Am. Chem. Soc. 85: 2149; Davis et al. (1985), Biochem. Intl. 10: 394-414; Stewart and Young (1969), Solid Phase Peptide Synthesis; U.S. Pat. No. 3,941,763; Finn et al. (1976), The Proteins (3rd ed.) 2: 105-253; and Erickson et al. (1976), The Proteins (3rd ed.) 2: 20 257-527. Solid phase synthesis is the preferred technique of making individual peptides since it is the most cost-effective method of making small peptides.

Compounds that contain derivatized peptides or which contain non-peptide groups may be synthesized by well-known organic chemistry techniques.

## 25           **Uses of the Compounds**

In general. The compounds of this invention have pharmacologic activity resulting from the pharmacologically active molecules to which the Fc is attached. The activity of these compounds can be measured by assays known in the art.

In addition to therapeutic uses, the compounds of the present invention may also be useful in diagnosing diseases characterized by dysfunction of an associated protein of interest. In one embodiment, a method of detecting in a biological sample a protein of interest (e.g., a receptor) that is capable of being activated comprising the steps of: (a) contacting the sample with a compound of this invention; and (b) detecting activation of the protein of interest by the compound. The biological samples include tissue specimens, intact cells, or extracts thereof. The compounds of this invention may be used as part of a diagnostic kit to detect the presence of their associated proteins of interest in a biological sample. Such kits employ the compounds of the invention having an attached label to allow for detection. The compounds are useful for identifying normal or abnormal proteins of interest. For the EPO-mimetic compounds, for example, presence of abnormal protein of interest in a biological sample may be indicative of such disorders as Diamond Blackfan anemia, where it is believed that the EPO receptor is dysfunctional.

### Pharmaceutical Compositions

In General. The present invention also provides methods of using pharmaceutical compositions of the inventive compounds. Such pharmaceutical compositions may be for administration for injection, or for oral, pulmonary, nasal, transdermal or other forms of administration. In general, the invention encompasses pharmaceutical compositions comprising effective amounts of a compound of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite),

preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol); incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hyaluronic acid may also be used, and this may have the effect of 5 promoting sustained duration in the circulation. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712 which are herein incorporated by reference. The 10 compositions may be prepared in liquid form, or may be in dried powder, such as lyophilized form. Implantable sustained release formulations are also contemplated, as are transdermal formulations.

Pulmonary delivery forms. Also contemplated herein is pulmonary delivery of the Fc fusion molecules (or derivatives thereof). The protein (or 15 derivative) is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. (Other reports of this include Adjei *et al.*, Pharma. Res. (1990) 7: 565-9; Adjei *et al.* (1990), Internat. J. Pharmaceutics 63: 135-44 (leuprolide acetate); Braquet *et al.* (1989), J. Cardiovasc. Pharmacol. 13 (suppl.5): s.143-146 (endothelin- 20 1); Hubbard *et al.* (1989), Annals Int. Med. 3: 206-12 ( $\alpha$ 1-antitrypsin); Smith *et al.* (1989), J. Clin. Invest. 84: 1145-6 ( $\alpha$ 1-proteinase); Oswein *et al.* (March 1990), "Aerosolization of Proteins", Proc. Symp. Resp. Drug Delivery II, Keystone, Colorado (recombinant human growth hormone); Debs *et al.* (1988), J. Immunol. 140: 3482-8 (interferon- $\gamma$  and tumor necrosis factor  $\alpha$ ) 25 and Platz *et al.*, U.S. Patent No. 5,284,656 (granulocyte colony stimulating factor).

Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered

dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art. Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Missouri; the 5 Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colorado; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Massachusetts.

All such devices require the use of formulations suitable for the 10 dispensing of the inventive compound. Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to diluents, adjuvants and/or carriers useful in therapy.

The inventive compound should most advantageously be 15 prepared in particulate form with an average particle size of less than 10  $\mu\text{m}$  (or microns), most preferably 0.5 to 5  $\mu\text{m}$ , for most effective delivery to the distal lung.

Pharmaceutically acceptable carriers include carbohydrates such 20 as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations may include DPPC, DOPE, DSPC and DOPC. Natural or synthetic surfactants may be used. PEG may be used (even apart from its use in derivatizing the protein or analog). Dextrans, such as cyclodextran, may be used. Bile salts and other related enhancers may be used. Cellulose and cellulose derivatives may be used. Amino 25 acids may be used, such as use in a buffer formulation.

Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.

Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise the inventive compound dissolved in

water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation may also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to 5 reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.

Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the inventive compound suspended in a propellant with the aid of a surfactant. The 10 propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include 15 sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing the inventive compound and may also include a bulking agent, such as lactose, sorbitol, sucrose, 20 mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.

Nasal delivery forms. Nasal delivery of the Fc fusion molecule is also contemplated. Nasal delivery allows the passage of the protein to the blood stream directly after administering the therapeutic product to the 25 nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran. Delivery via transport across other mucous membranes is also contemplated.

Dosages. The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the age, condition, body weight, sex and diet of the patient, the severity of any infection, 5 time of administration and other clinical factors. Generally, the daily regimen should be in the range of 0.1-1000 micrograms of the inventive compound per kilogram of body weight, preferably 0.1-150 micrograms per kilogram.

**Specific preferred embodiments**

**Working examples**

10 The following disclosure(s) are illustrative rather than limiting.

**Example 1**

Identification of cysteines in a Fc construct of osteoprotegerin by CDAP labeling and alkaline-induced cleavage with LC-MS analysis

15 **Abstract**

Purpose. To assay for cysteines in a Fc construct of Osteoprotegerin stored in acidic media and to ascertain their location.

Methods. The reagent 1-cyano-4-dimethylamino-pyridinium tetrafluoroborate (CDAP) was employed to selectively cyanlate stable 20 free-sulphydryl groups at pH 4. Cyanlation reactions were analyzed by HPLC coupled with mass-spectral analysis (LC-MS). Reversed-phase HPLC was used to separate component peaks from the native and CDAP-reacted samples. The reversed-phase samples were collected, introduced 25 into a solution of aqueous ammonium hydroxide plus guanidine hydrochloride and subsequently analyzed by LC-MS. **Results.** Reversed-phase HPLC analysis of Fc-Osteoprotegerin gave two peaks. LC-MS of the primary CDAP reaction revealed selective cyanlation of two-sulphydryl groups in a peak that represents approximately 10% of the proteinaceous material; the peak representing approximately 90% of the material was not

cyanylated after reaction with CDAP. Analysis of the ammonium/guanidine treated isoforms by LC-MS detailed the location of two free cysteine-sulphydryl groups.

**Conclusions.** A reversed-phase separable form of Fc-

5 Osteoprotegerin contains two free sulphydryl groups. CDAP is an effective reagent for characterizing the free-sulphydryl groups of proteins in acidic conditions.

**Introduction**

**Fc-OPG, a construct of the naturally occurring cytokine**

10 Osteoprotegerin (OPG), is under clinical investigation for utility in the treatment of osteoporosis. Fc-OPG is a homodimeric, high molecular weight protein (91 kD) containing 24 cysteines in each monomer sequence. All cysteines in the dimer are covalently associated through 24 disulfide bonds (or cystine). These covalent linkages play a crucial role in

15 maintaining the tertiary and quaternary structure of the protein. Therefore, unpaired cysteines may result in a decrease in biological activity, have immunogenic effects, or be a precursor to further physical and chemical instability (oxidation and aggregation).

Monitoring the state of cysteine side-chains—in the disulfide form

20 of cystine or sulphydryl of cysteine—is commonly accomplished by labeling the free sulphydryl groups with a thiol specific fluorophor or molecular weight tag under alkaline conditions. Given the labile nature of cysteine-sulphydryl groups and cystine-disulfides in alkaline aqueous media (pKa's ~8), quantitative detection of free cysteine-sulphydryl is

25 subject to inaccuracy resulting from cystine reduction at high pH and cysteine related disulfide formation. Alkaline condition labeling methods may not be suitable for estimating the free-cysteine-sulphydryl present in acidic formulations of proteins.

A reverse-phase HPLC separable isoform of Fc-OPG was observed to be reactive to the addition of aqueous CuCl<sub>2</sub>. After reaction with CuCl<sub>2</sub>, the isoform eluted with the same retention time as the main peak in the reverse-phase chromatogram. The nature of this reactivity led to

5   speculation that the isoform was representative of free-sulphydryl groups in the protein that were converted to cystine with the aid of a copper oxidant. Numerous techniques were employed to compare the number of free cysteine-sulphydryl groups present in the main peak versus the isoform. No differences were found. A commonality between all of the

10   techniques was the use of neutral to alkaline reaction conditions.

This example presents the characterization of the isoform using the reagent 1-cyano-4-dimethylamino-pyridinium tetrafluoroborate (CDAP). The detection and identification of unpaired cysteine residues present in acidic media is made possible by the cyanylation of free cysteine

15   sulphydryl groups by CDAP (Figure 6) and subsequent peptide bond cleavage at the cyanlated cysteine residues (Figure 7).

#### Materials

The Fc construct of OPG can be prepared by processes known in the art. CDAP can be purchased from Sigma-Aldrich (St. Louis, MO).

#### 20   Methods

RP-HPLC: Samples were injected into a Zorbax 300SB C8 4.6mm x 25cm column and eluted with a gradient of 0.1 % TFA and 0.1% TFA in 90% ACN at 60 °C on a Hewlett-Packard 1100 or 1090 at 215 nm.

25   Electrospray Mass Spectrometry: All mass spectrometry was performed on a Perkin-Elmer/Sciex AP100 spectrometer using conditions consistent with ionization of peptides and proteins.

Copper Treatment: Ten mg/ml protein in 10mM sodium acetate and 5% sorbitol was treated with 50 mM CuCl<sub>2</sub> (final pH ~4).

Cyanylation Conditions: A solution of 50 mg/mL of CDAP in 0.5 M HCl was prepared. 50  $\mu$ L of the CDAP solution was added to 500  $\mu$ L of 10mg/mL of protein in pH 5 acetate (10 mM) and 5% sorbitol. 5  $\mu$ L of 0.1 N NaOH was added to the protein-CDAP mixture and vortexed.

5        Cleavage Conditions: The cyanylated protein was separated from native material by reverse-phase HPLC and both peaks were collected. The fractions were reduced in volume by approximately two-thirds under vacuum then treated with a solution of 1.5 M NH<sub>4</sub>OH, 4 M GdHCl and heated at 37 °C for 90 minutes.

10      **Discussion**

15        Cyanylation of two cysteine sulphydryl groups in Fc-OPG would give a mass increase of 50 daltons resulting from the addition of two 26 dalton cyanide groups and the assumed loss of two protons from the cysteine side chains. The selective cyanylation of the RP-HPLC isoform is evident in the ~50 dalton mass increase detected for that peak; the main peak mass was unmodified. The nature of the isoform was further indicated by the observation that the isoform was no-longer responsive to the addition of CuCl<sub>2</sub>. A pair of cyanylated cysteines would not be competent for disulfide formation via CuCL<sub>2</sub> oxidation (Figure 8).

20        The cleavage pattern observed for the CDAP reacted and ammonium hydroxide treated isoform differed greatly from that of the main peak. The isoform cleavage reaction produced three distinct peaks and the main peak reaction resulted in one peak (Figure 9). Mass spectrometry of the isoform cleavage products established their identity 25 (Table 1). The peak with mass of 22,270 amu correlated with a fragment of the molecule consisting of the entire amino acid sequence C-terminal of the last cysteine in the Fc sequence (Figure 9, peak 2). The mass found for peak 3 in Figure 4, 6616.8 amu, is equivalent to the mass of a Fc-domain disulfide loop corresponding to the Fc sequence found N-terminally to the

fragment determined for peak 2. Peak 4 (Figure 9) correlates with the remaining piece of the Fc-OPG construct. These results reveal two free-cysteine-sulphydryl groups in the Fc domain of one of the two monomers (Figure 10).

5 In subsequent experiments, the RP-HPLC isoform was converted to main peak under alkaline-denaturing conditions (data not shown). Apparently, formation of cystine in the isoform was rapid enough in those alkaline conditions to go undetected by other techniques (Ellman's reaction and peptide mapping). The site specificity and acid-condition-  
10 compatibility of CDAP for labeling cysteine residues made possible the characterization of this protein isoform.

### Conclusions

15 A reversed-phase HPLC separable isoform of Fc-OPG contains two free sulphydryl groups. The detection of free cysteine sulphydryl groups in a protein can be complicated by their transient nature in the alkaline conditions typically used for analysis. CDAP is an effective reagent for characterizing the free-sulphydryl groups of proteins in acidic conditions.

### Example 2

20 Purpose. Significant differences were observed in the stability of Fc-OPG as a function of copper treatment of the bulk protein, where Fc-OPG treated with copper was significantly more stable than Fc-OPG that was not. Specifically, the Fc-OPG that was not treated with copper was more prone to aggregation than the copper-treated Fc-OPG. The improved stability of Fc-OPG is thought to be due to the conversion of an  
25 unstable fraction of Fc-OPG with incomplete disulfide structure to a form with intact disulfide bonding upon treatment with copper ion.

Methods. Reversed-phase chromatography: Reversed-phase chromatography was performed on a Hewlett-Packard 1100 or 1090 HPLC system equipped with a diode-array detector and controlled by

Chemstation Software. Fc-OPG samples were analyzed on a Zorbax (4.6 mm X 25 cm) 300SB column. The column is initially equilibrated at 90% buffer A (HPLC grade water containing 0.1% TFA). The samples were eluted with a linear gradient of 4.2% buffer B/min (90% acetonitrile, 10% HPLC grade water and 0.1% TFA) for 6 minutes then 0.11% buffer B/min over 37 minutes. The column was heated at 60 °C and elution was monitored 215 nm at a flow rate of 0.5 ml/min. Both copper and non-copper treated Fc-OPG (10 mg/mL) were formulated in 10 mM sodium acetate, pH 5.0, containing 5% sorbitol. Samples were incubated at 29 °C and analyzed over time.

Conclusions. As has been previously shown, CuCl<sub>2</sub> catalyzes the formation of cystine from two unpaired cysteines in Fc-OPG. The reversed-phase profiles of a Fc-OPG preparation after copper treatment versus one which was untreated are compared in Figure 11. The prominent post-peak in the chromatogram of the untreated sample is due to the population of Fc-OPG molecules with unpaired cysteines. The stability of these Fc-OPG preparations was examined as a function of copper treatment by size-exclusion HPLC. The chromatograms of untreated and copper-treated Fc-OPG incubated at 29 °C for 2 years are shown in Figure 12; an increase in high molecular weight aggregate and dimer peaks are evident in the untreated sample.

### Abbreviations

The abbreviations used throughout this specification are defined as follows, unless otherwise defined in specific instances:

CDAP	1-cyano-4-dimethylamino-pyridinium tetrafluoroborate
HPLC	high performance liquid chromatography
ITZ	iminothiazolidine

OPG	osteoprotegerin
RP	reversed-phase
TNF	tumor necrosis factor
TPO	thrombopoietin

5

\* \* \*

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto, without departing from the spirit and scope of the invention as set forth herein.

**What is claimed is:**

1. A process for preparing a pharmacologically active compound, which comprises:
  - (a) preparing a pharmacologically active compound comprising an Fc domain;
  - (b) treating the pharmacologically active compound with a copper (II) halide; and
  - (c) isolating the treated fusion molecule.
2. The process of Claim 1, wherein the pharmacologically active compound is a fusion molecule comprising a pharmacologically active domain and an Fc domain.
3. The process of Claim 1, wherein the pharmacologically active compound comprises an antibody.
4. The process of Claim 1, wherein the copper (II) halide is CuCl<sub>2</sub>.
5. The process of Claim 1, wherein the pharmacologically active compound is prepared in E coli.
6. The process of Claim 4, wherein the copper (II) halide is CuCl<sub>2</sub>.
7. The process of Claim 6, wherein the CuCl<sub>2</sub> is used in a concentration of at least about 10 mM.
8. The process of Claim 1, wherein the pharmacologically active compound is prepared in CHO cells.
9. The process of Claim 8, wherein the copper (II) halide is CuCl<sub>2</sub>.
10. The process of Claim 9, wherein the CuCl<sub>2</sub> is used in a concentration of at least about 30 mM.
- 25 11. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of an OPG protein.
12. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of a leptin protein.

13. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of a TNF- $\alpha$  inhibitor.
14. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of an IL-1 inhibitor.
- 5 15. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of an IL-1ra protein.
16. The process of Claim 2, wherein the pharmacologically active domain comprises the sequence of a TPO-mimetic peptide.
17. A process for preparing a pharmacologically active compound, which 10 comprises:
  - (a) preparing a pharmacologically active compound comprising an Fc domain;
  - (b) treating the fusion molecule with guanidine HCl at a concentration of at least about 4 M;
  - 15 (c) increasing the pH to about 8.5; and
  - (d) isolating the treated fusion molecule.
18. The process of Claim 17, wherein the pharmacologically active compound is a fusion molecule comprising a pharmacologically active domain and an Fc domain.
- 20 19. The process of Claim 17, wherein the pharmacologically active compound comprises an antibody.
20. The process of Claim 17, wherein the pharmacologically active compound is prepared in E. coli.
21. The process of Claim 18, wherein the pharmacologically active compound is prepared in CHO cells.
- 25 22. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of an OPG protein.
23. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of a leptin protein.


24. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of a TNF- $\alpha$  inhibitor.
25. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of an IL-1 inhibitor.
- 5 26. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of an IL-1ra protein.
27. The process of Claim 18, wherein the pharmacologically active domain comprises the sequence of a TPO-mimetic peptide.
28. The process of Claim 1, wherein the Fc domain is an IgG1 Fc domain.
- 10 29. The process of Claim 17, wherein the Fc domain is an IgG1 Fc domain.
30. The process of Claim 1, wherein the Fc domain comprises the sequence of SEQ ID NO: 2.
31. The process of Claim 17, wherein the Fc domain comprises the sequence of SEQ ID NO: 2.

15

1 / 12

## FIG. 1


Standard Ecoli FcOPG Vs Ecoli FcOPG+10mM Cu



2 / 12


# FIG. 2

FcOPG after Labeling with CDAP




**FIG. 3**

FcOPG after labeling with CDAP,  
Subsequent base Cleavage  
and LC/MS analysis



4 / 12

FIG. 4

CHO-OPG-Fc Vs CHO-OPG-Fc + 30mM CuCl<sub>2</sub>

— DAD1 A, sig=215,4 Ref=550,40 of CHOOPCU3\002-0401.D  
- - - DAD1 A, sig=215,4 Ref=550,40 of CHOOPCU3\000-0201.D

5 / 12  
FIG. 5A

ATGGACAAA ACTCACACATGTCCACCTGTCCAGCTCCGGA ACTCCTGGGGGACCGTCA  
 1 -----+-----+-----+-----+-----+ 60  
 TACCTGTTTGAGTGTACAGGTGGAACAGGTGAGGCCTTGAGGACCCCCCTGGCAGT

a M D K T H T C P P C P A P E L L G G P S -

GTCTCCTCTTCCCCAAAACCCAAGGACACCCTCATGATCTCCGGACCCCTGAGGTC  
 61 -----+-----+-----+-----+-----+ 120  
 CAGAAGGAGAAGGGGGTTTGGGTTCTGTGGAGTACTAGAGGCCCTGGGACTCCAG

a V F L F P P K P K D T L M I S R T P E V -

ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTG  
 121 -----+-----+-----+-----+-----+ 180  
 TGTACGCACCACCTGCACTCGGTGCTCTGGGACTCCAGTTCAAGTTGACCATGCAC

a T C V V V D V S H E D P E V K F N W Y V -

GACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACACCGACG  
 181 -----+-----+-----+-----+-----+ 240  
 CTGCCGCACCTCCACGTATTACGGTTCTGTTGGCGCCCTCGTCATGTTGCGTGC

a D G V E V H N A K T K P R E E Q Y N S T -

TACCGTGTGGTCAGCGCCTCACCGCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC  
 241 -----+-----+-----+-----+-----+ 300  
 ATGGCACACCACTCGCAGGAGTGGCAGGACGTGGCCTGACCGACTTACCGTTCTCATG

a Y R V V S V L T V L H Q D W L N G K E Y -

AAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCATCGAGAAAACCATCTCAAAGCC  
 301 -----+-----+-----+-----+-----+ 360  
 TTACGTTCCAGAGGTTGTTGGAGGGTAGCTCTTGGTAGAGGTTTCGG

a K C K V S N K A L P A P I E K T I S K A -

AAAGGGCAGCCCCGAGAACCAACAGGTGTACACCCCTGCCCATCCGGGATGAGCTGACC  
 361 -----+-----+-----+-----+-----+ 420  
 TTTCCCGTCGGGCTCTGGTGTCCACATGTGGGACGGGGTAGGGCCCTACTCGACTGG

a K G Q P R E P Q V Y T L P P S R D E L T -

AAGAACCAAGGTCAAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGTG  
 421 -----+-----+-----+-----+-----+ 480  
 TTCTGGTCCAGTCGGACTGGACGGACCAGTTCCGAAGATAGGGTCGCTGTAGCGGCAC

a K N Q V S L T C L V K G F Y P S D I A V -

GAGTGGGAGAGCAATGGCAGCCGGAGAACAAACTACAAGACCACGCCCTCCGTGCTGGAC  
 481 -----+-----+-----+-----+-----+ 540  
 CTCACCCCTCTCGTTACCGCCTCTGTTGATGTTCTGGTGCAGGGCACGACCTG

a E W E S N G Q P E N N Y K T T P P V L D -

TCCGACGGCTCCTCTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAG  
 541 -----+-----+-----+-----+-----+ 600  
 AGGCTGCCGAGGAAGAAGGAGATGTCGTTGAGTGGCACCTGTTCTCGTCCACCGTC

6 / 12

## FIG. 5B

a S D G S F F L Y S K L T V D K S R W Q Q -

GGGAACGTCTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAG  
601 -----+-----+-----+-----+-----+ 660

CCCTTGCAGAAGAGTACGAGGCCTACGTACTCCGAGACGTGTTGGTATGTGCGTCTTC

a G N V F S C S V M H E A L H N H Y T Q K -

AGCCTCTCCCTGTCTCCGGTAAA

661 -----+-----+ 684

TCGGAGAGGGACAGAGGCCATT

a S L S L S P G K

7 / 12

FIG. 6





FIG. 7



itz-peptide, mass gain of 26 Da  
peptide

8 / 12

FIG. 8A






FIG. 8B




9 / 12

FIG. 8C




1 0 / 1 2

FIG. 9




11 / 12

**FIG. 10A**  
Reversed-phase isoform




**FIG. 10B**  
Reversed-phase main peak




12 / 12  
FIG. 11

Reversed-phase HPLC of untreated (upper trace) and copper treated (lower trace) FcOPG.



## FIG. 12

Size-exclusion HPLC of FcOPG after 2 years incubation at 29°C; copper treated FcOPG (lower trace) and untreated FcOPG (upper trace).



## SEQUENCE LISTING

<110> AMGEN INC.  
<120> PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES  
<130> A-584  
<140> To Be Assigned  
<141> 2000-11-09  
<150> 60/165,188  
<151> 1999-11-12  
<160> 2  
<170> PatentIn version 3.0  
<210> 1  
<211> 684  
<212> DNA  
<213> Homo sapiens  
<220>  
<221> CDS  
<222> (1)...(684)  
<400> 1  
atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc ctg  
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu  
1 5 10 15  
ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc  
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu  
20 25 30  
atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gac gtg agc  
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser  
35 40 45  
cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag  
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu  
50 55 60  
gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg  
Val His Asn Ala Lys Thr Lys Pro Arg Glu Gln Tyr Asn Ser Thr  
65 70 75 80  
tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat  
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn  
85 90 95  
ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc  
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro  
100 105 110  
atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag  
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln  
115 120 125  
gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc  
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val  
130 135 140

agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg 480  
 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val  
 145 150 155 160

gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct 528  
 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Thr Thr Pro  
 165 170 175

ccc gtg ctg gac tcc gac ggc tcc ttc ctc tac agc aag ctc acc 576  
 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr  
 180 185 190

gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg 624  
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val  
 195 200 205

atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg 672  
 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu  
 210 215 220

tct ccg ggt aaa 684  
 Ser Pro Gly Lys  
 225

<210> 2  
 <211> 228  
 <212> PRT  
 <213> Homo sapiens

<400> 2

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu  
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu  
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser  
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu  
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr  
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn  
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro  
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln  
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val  
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val  
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro  
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr  
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val  
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu  
210 215 220

Ser Pro Gly Lys  
225

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/30798

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 C07K1/113

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, CANCERLIT, LIFESCIENCES, EMBASE, CHEM ABS Data, SCISEARCH, BIOSIS, EPO-Internal, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 572 798 A (KOTHS KIRSTON E ET AL) 25 February 1986 (1986-02-25) column 2, line 23-53 column 9, line 40 -column 10, line 24 column 11, line 63 -column 12, line 68 ----	1-31
A	US 5 654 403 A (RIVEROS-ROJAS VALENTINA ET AL) 5 August 1997 (1997-08-05) column 2, line 36 -column 3, line 42 claims ----	1-31
A	WO 98 48024 A (SANICOLA NADEL MICHELLE ;BIOGEN INC (US); CATE RICHARD (US); GOTWA) 29 October 1998 (1998-10-29) page 19 -page 20 claim 4 ----	30,31
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

21 February 2001

Date of mailing of the international search report

06/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Covone, M

## INTERNATIONAL SEARCH REPORT

Intern: Application No  
PCT/US 00/30798

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	MEREWETHER LEE ANNE ET AL: "Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in <i>Escherichia coli</i> ." ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS., vol. 375, no. 1, 1 March 2000 (2000-03-01), pages 101-110, XP000982456 ISSN: 0003-9861 the whole document -----	1-31

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/30798

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4572798	A 25-02-1986	AT 84540 T		15-01-1993
		AU 594930 B		22-03-1990
		AU 5005285 A		12-06-1986
		BR 8506101 A		19-08-1986
		CA 1248300 A		03-01-1989
		DE 3586987 A		25-02-1993
		DE 3586987 T		13-05-1993
		EP 0185459 A		25-06-1986
		ES 549135 D		01-09-1986
		ES 8700271 A		01-01-1987
		GB 2168055 A, B		11-06-1986
		IN 163025 A		30-07-1988
		JP 1965673 C		25-08-1995
		JP 6096600 B		30-11-1994
		JP 61140600 A		27-06-1986
		KR 9303475 B		22-04-1994
		ZA 8509001 A		27-08-1986
US 5654403	A 05-08-1997	AT 161191 T		15-01-1998
		AU 674290 B		19-12-1996
		AU 2872992 A		07-06-1993
		CA 2121257 A		13-05-1993
		DE 69223641 D		29-01-1998
		DE 69223641 T		09-04-1998
		DK 612251 T		27-04-1998
		EP 0612251 A		31-08-1994
		ES 2112338 T		01-04-1998
		WO 9308837 A		13-05-1993
		GR 3025931 T		30-04-1998
		HK 1004325 A		20-11-1998
		IL 103560 A		08-02-1998
		JP 2881499 B		12-04-1999
		JP 7502497 T		16-03-1995
		SG 47905 A		17-04-1998
		US 5792838 A		11-08-1998
		ZA 9208296 A		28-04-1994
WO 9848024	A 29-10-1998	AU 7120898 A		13-11-1998
		BR 9808934 A		01-08-2000
		CN 1257545 T		21-06-2000
		EP 0975771 A		02-02-2000
		NO 994998 A		20-12-1999
		PL 336306 A		19-06-2000
		TR 9902878 T		21-02-2000

# Recombinant Human Interleukin 18

Code No.	Quantity	Form
B001-5	25 µg x 1 vial	lyophilized

**BACKGROUND:** Interleukin 18 (IL-18) is a 18 kDa novel cytokine which identified as a costimulatory factor for production of interferon- $\gamma$  (IFN-  $\gamma$ ) in response to toxic shock and shares functional similarities with IL-12. IL-18 is synthesized as a precursor 24 kDa molecule without a signal peptide and must be cleaved to produce an active molecule. IL-1 converting enzyme (ICE, Caspase-1) cleaves pro-IL-18 at aspartic acid in the P1 position, producing the mature, bioactive peptide that is readily released from the cells. It is reported that IL-18 is produced from Kupffer cells, activated macrophages, keratinocytes, intestinal epithelial cells, osteoblasts, adrenal cortex cells and murine diencephalon.

IFN-  $\gamma$  is produced by activated T or NK cells and plays critical roles in the defense against microbial pathogens. IFN-  $\gamma$  activates macrophages, enhances NK activity and B cell maturation, proliferation and Ig secretion, induces MHC class I and II antigens, and inhibits osteoclast activation.

IL-18 acts on T helper 1-type T cells and in combination with IL-12 strongly induces them to produce IFN-  $\gamma$ . Pleiotropic effects of IL-18 has also been reported, such as, enhancement production of IFN-  $\gamma$  and GM-CSF in peripheral blood mononuclear cells, production of T helper type 1 cytokines, IL-2, GM-CSF and IFN-  $\gamma$  in T cells, enhancement of Fas ligand expression by T helper type 1 (Th1) cells.

**DESCRIPTION :** cDNA encoding the matured Human IL-18 protein sequence (corresponding to a.a. 37-193) was expressed in *E. coli*.

**PURITY :** Greater than 90% purity as confirmed on SDS-PAGE by Coomassie brilliant blue staining.

**MOLECULAR WEIGHT:** 18kDa

**ENDOTOXIN LEVEL:** Less than 0.1 ng per 1 µg of recombinant IL-18 protein, measured by LAL method.

**SUPPLIED :** Lyophilized in PBS, 0.1% BSA and 1 % sucrose. Reconstitute in 100 µl of ice-cold distilled water on ice.

**STORAGE :** Lyophilized IL-18 is stable for 24 months from the date of manufacture when stored at -20°C or below. After reconstitution, avoid repeated freeze/thaw cycles. The IL-18 can be stored for 1 week at 4°C. For storage, prepare appropriate aliquots and freeze them at -80°C.

**ACTIVITY :** Induction of IFN- $\gamma$  by KG-1 cell (Human myelomonocyte; ATCC CCL246) in response to the Human IL-18 was measured by Human IFN- $\gamma$  ELISA. The activity of lot 030 is as follow;

IL-18 conc. (ng/mL)	IFN- $\gamma$ induction (IU/mL)*
40	58.0
80	200.7

\*IFN- $\gamma$  producing activity of the sample cells can vary depending on cell conditions.

**IFN- $\gamma$  PRODUCTION ASSAY :**

- 1) KG-1 cells were cultured at 3X 10<sup>5</sup>cells/mL for 4 days at 37°C in 5% CO<sub>2</sub> incubator with RPMI 1640 containing 10% fetal calf serum.
- 2) After four days of preculture, the cell concentration was adjusted to 3X 10<sup>6</sup>cells/mL and incubated for 24 hours at 37°C in 5% CO<sub>2</sub> incubator with RPMI 1640 containing 10% fetal calf serum in the presence of IL-18.
- 3) The culture supernatant were recovered and the amount of IFN- $\gamma$  were measured by Human IFN- $\gamma$  ELISA (code# IM1743: MBL).

**RESEARCH USE :** For research use only. Not for use in *in vitro* diagnostic procedures for clinical diagnosis.

**REFERENCE:**

- 1) Okamura H., et al. *Nature* 378, 88-91 (1995)
- 2) Ushio S., et al. *J. Immunol.* 156, 4274-4279 (1996)
- 3) Micallef M., et al. *Eur. J. Immunol.* 26, 1647-1651 (1996)
- 4) Tao D, et al. *Cell Immunol.* 173, 230-235 (1998)

B001-5

October 09, 2003

MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.

15 B Constitution Way, Woburn, MA 01801

Tel. (781)939-6964 Fax. (781)939-6963 www. mblintl.com